The 13th Five-Year Plan for the pharmaceutical industry is about to be released.

It is said that experts involved in the formulation of the plan said that in May, the "13th Five-Year Plan" for the pharmaceutical industry is expected to be released, and it has now been signed by the ministries and committees and submitted to the State Council for approval.

According to the above-mentioned experts who participated in the formulation of the plan, the key word of the 13th Five-Year Plan for the pharmaceutical industry is to encourage drug innovation. The specific contents include giving priority to listing innovative drugs on the market in the medical insurance catalogue, including innovative drugs in the "green channel" for new drug approval, and innovative drugs will be supported by policies and industrial funds. Standards guide pharmaceutical companies to take the road of internationalization.

In 2016, the consistency evaluation of Chinese generic drugs is about to start, and the industry reshuffle after the evaluation is inevitable. According to the statement mentioned in the "Opinions on Carrying out the Consistency Evaluation of the Quality and Efficacy of Generic Drugs" issued by the State Council, "For the generic drugs that domestic drug manufacturers have been approved to market in the European Union, the United States and Japan, the relevant materials that can be registered and declared abroad are: Based on the new registration classification of chemical drugs, the drug is declared for marketing, and it is deemed to have passed the consistency evaluation after it is approved for marketing; drugs that are produced and marketed on the same production line in China and approved for marketing in the European Union, the United States and Japan are deemed to have passed the consistency evaluation.”

This means that Chinese pharmaceutical companies taking the road of "internationalization" will enjoy the policy benefits of simplifying the process in the evaluation of drug consistency, so as to obtain the approval number first and seize the "three seats". According to the policy, if there are more than three manufacturers of the same variety of drugs that have passed the consistency evaluation, the drugs that have not passed the consistency evaluation will no longer be selected for centralized procurement of drugs.